Vivek Nagaraja
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Vivek Nagaraja has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Dinesh Khanna
Division of Rheumatology, University of Michigan , Ann Arbor, MI
2 shared publications - Athol Umfrey Wells
Interstitial Lung Disease Unit, Royal Brompton Hospital & Imperial College London UK
1 shared publication - Chi-Hong Tseng
Division of General Internal Medicine and Health Services Research, Department of Medicine, University of California , Los Angeles, CA 90024
1 shared publication - Daniel E. Furst
Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
1 shared publication - Donald P. Tashkin
Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
1 shared publication - Fereidoun Abtin
Department of Radiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
1 shared publication
Latest Publications
- Open Access
- 23 December 2015
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 17 (1) , 372
Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis–associated interstitial lung disease trials
The extent of lung involvement visualized by high-resolution computed tomography (HRCT) is a predictor of decline in forced vital capacity (FVC) in scleroderma–interstitial lung disease. Our objective was to evaluate the performance of three different HRCT-defined staging systems in the Scleroderma Lung Study I (SLS I) over a 1-year period. We assessed two visual semiquantitative scores: the maximum fibrosis score (MaxFib, the fibrosis score in the zone of maximal lung involvement) and visual assessment of total lung involvement (TLI) as proposed by Goh and Wells. In addition, we evaluated the computer-aided diagnosis and calculated the quantitative percentage with fibrosis (QLF) and TLI. The mean duration of the disease was 3.2 years, and the mean FVC was 67.7 %. Regardless of the staging system used, a greater degree of fibrosis/TLI on HRCT scans was associated with a greater decline in FVC in the placebo group. Using the MaxFib and QLF, the mean absolute changes in FVC from baseline were 0.1 % and −1.4 %, respectively, in 25 % involvement (negative score denotes worsening in FVC). Conversely, cyclophosphamide was able to stabilize decline in FVC in subjects with greater degree of involvement detected by HRCT. Using the visual MaxFib and QLF, the mean absolute improvements in FVC were 1.2 and 1.1, respectively, with >25 % involvement. HRCT-defined lung involvement was a predictor of decline in FVC in SLS I. The choice of staging system for cohort enrichment in a clinical trial depends on feasibility. ClinicalTrials.gov identifier: NCT00004563 (Scleroderma Lung Study I) ISRCTN15982171. Registered 19 Aug 2015. The online version of this article (doi:10.1186/s13075-015-0872-2) contains supplementary material, which is available to authorized users.
- 23 December 2015
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 17 (1) , 372
Open AccessPredictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis–associated interstitial lung disease trials
The extent of lung involvement visualized by high-resolution computed tomography (HRCT) is a predictor of decline in forced vital capacity (FVC) in scleroderma–interstitial lung disease. Our objective was to evaluate the performance of three different HRCT-defined staging systems in the Scleroderma Lung Study I (SLS I) over a 1-year period. We assessed two visual semiquantitative scores: the maximum fibrosis score (MaxFib, the fibrosis score in the zone of maximal lung involvement) and visual assessment of total lung involvement (TLI) as proposed by Goh and Wells. In addition, we evaluated the computer-aided diagnosis and calculated the quantitative percentage with fibrosis (QLF) and TLI. The mean duration of the disease was 3.2 years, and the mean FVC was 67.7 %. Regardless of the staging system used, a greater degree of fibrosis/TLI on HRCT scans was associated with a greater decline in FVC in the placebo group. Using the MaxFib and QLF, the mean absolute changes in FVC from baseline were 0.1 % and −1.4 %, respectively, in 25 % involvement (negative score denotes worsening in FVC). Conversely, cyclophosphamide was able to stabilize decline in FVC in subjects with greater degree of involvement detected by HRCT. Using the visual MaxFib and QLF, the mean absolute improvements in FVC were 1.2 and 1.1, respectively, with >25 % involvement. HRCT-defined lung involvement was a predictor of decline in FVC in SLS I. The choice of staging system for cohort enrichment in a clinical trial depends on feasibility. ClinicalTrials.gov identifier: NCT00004563 (Scleroderma Lung Study I) ISRCTN15982171. Registered 19 Aug 2015. The online version of this article (doi:10.1186/s13075-015-0872-2) contains supplementary material, which is available to authorized users.
- 17 January 2015
- Published by Springer Nature in Current Treatment Options in Rheumatology
- Vol. 1 (1) , 82-105
Management of Gastrointestinal Involvement in Scleroderma
Opinion statement Gastrointestinal tract (GIT) is commonly involved in patients with systemic sclerosis (SSc). The GI involvement is quite heterogeneous varying from asymptomatic disease to significant dysmotility causing complications like malabsorption, weight loss, and severe malnutrition. This review focuses on the management of GI involvement in SSc and has been categorized based on the segment of GIT involved. A brief discussion on the role of patient-reported outcome measures in SSc-GI involvement has also been incorporated.
- 17 January 2015
- Published by Springer Nature in Current Treatment Options in Rheumatology
- Vol. 1 (1) , 82-105
Management of Gastrointestinal Involvement in Scleroderma
Opinion statement Gastrointestinal tract (GIT) is commonly involved in patients with systemic sclerosis (SSc). The GI involvement is quite heterogeneous varying from asymptomatic disease to significant dysmotility causing complications like malabsorption, weight loss, and severe malnutrition. This review focuses on the management of GI involvement in SSc and has been categorized based on the segment of GIT involved. A brief discussion on the role of patient-reported outcome measures in SSc-GI involvement has also been incorporated.